Facebook
Twitter
LinkedIn
ForwardFundamentals in Urology (2016)
The Fundamentals in Urology course is designed to apply basic science knowledge and principles in development of treatment algorithms. This 4-day course will provide attendees with valuable skills in developing a rational methodological approach to application of knowledge which will contribute to positive outcomes for patients. Attendees will discover the importance of the study of basic sciences and how it transfers into the lifelong learning process and medical practice. This course is designed to ensure a fundamental knowledge of the "why" behind a broad expanse of general urologic conditions. A thorough knowledge of the basic science behind the treatments will allow for better counseling and education of patients by all clinical urologic practitioners.
Target Audience
- Urology residents
- Allied Health Professionals
Learning Objectives
At the conclusion of this course, participants should be able to:
- Identify specific applications of basic science knowledge and principles in development of treatment methods
- Develop a scientific and methodological approach to the application of knowledge gained at the conference that is consistent with AUA guidelines and best practices
- Compare newly published findings and their impact on medical practice and patient care
- Transfer continuing study of basic sciences into lifelong learning process and medical practice
- Articulate the rationale for their treatment approach concisely to the patient and modify the treatment plan as circumstances change
Saturday, June 11, 2016
6:45 – 8:00 am Continental Breakfast and Registration
8:00 – 8:15 am Welcome, Introduction
Session: Nephrolithiasis and Advanced Prostate Cancer
8:15 – 9:15 am Nephrolithiasis 1: The Physiology of Stones
Glenn M. Preminger, MD
9:15 – 10:15 am Nephrolithiasis 2: Metabolic Work-up and Treatment of Stones
Glenn M. Preminger, MD
10:15 – 10:30 am Break
10:30 – 11:30 am Management of Advanced Prostate Cancer: Drugs, Mechanisms, Disease, Epidemiology and Molecular Mechanisms
Michael B. Williams, MD
11:30 – 11:45 am AUA Update: Core Curriculum
Victor Nitti, MD
11:45 am – 12:45 pm Lunch & Learn with the Experts
Session: Incontinence, Infections, and Pelvic Pain
12:45 – 1:45 pm Pelvic Organ Prolapse and SUI: Mechanisms and Mechanics
Catherine Matthews, MD
1:45 – 2:45 pm UTIs: Pattern and Pathophysiology
Michael A. Liss, MD, MAS
2:45 – 3:00 pm Break
3:00 – 4:00 pm Interstitial Cystitis and Disorders of Pelvic Pain
Robert J. Evans, MD, FACS
4:00 – 4:30 pm Q&A Session
5:30 – 7:00 pm Reception
Sunday, June 12, 2016
7:00 – 8:00 am Continental Breakfast
Session: Minimally Invasive Surgery, BPH, Ethics, and Renal Oncology
8:00 – 9:00 am Lasers, Laparoscopes, and Lithotripters: The Science of Minimally Invasive
Urology
Jay D. Raman, MD
9:00 – 10:00 am BPH and LUTS in Men: Pathophysiology and Evaluation
Richard K. Lee, MD
10:00 – 10:15 am Break
10:15 – 11:15 am Uro-Ethics
Eric A. Singer, MD
11:15 am – 12:45 pm Molecular Genetics and Principles of Molecular Therapeutics of Kidney Cancer
W. Marston Linehan, MD
12:45 – 1:45 pm Lunch & Learn with the Experts
Session: Outcomes Research and Imaging
1:45 – 2:45 pm Application of Outcomes Research to Urologic Patients
Charles D. Scales Jr., MD
2:45– 3:00 pm Break
3:00 – 4:00 pm MRI for Urologists
Afshan Ornan, MD
4:00 – 4:15 pm Q&A Session
Monday, June 13, 2016
7:15 – 8:15 am Continental Breakfast
Session: Adrenal and Renal Physiology and Bowel Diversions
8:15 – 9:15 am Adrenal Physiology
Paul L. Crispen, MD
9:15 – 10:15 am Bowel Diversions: Physiology Underlying Electrolyte Abnormalities
Tracey L. Krupski, MD, MPH
10:15 – 10:30 am Break
10:30 – 11:30 am Renal Physiology Changes in Pathologic States
Necole Marie Streeper, MD
Session: The Bladder and Male Infertility
11:30 am – 12:30 pm Basic Science of Bladder Cancer
Trinity J. Bivalacqua, MD, PhD
12:30 – 1:30 pm Lunch & Learn with the Experts
1:30 – 1:45 pm AUA Update: Office of Research
1:45 – 3:15 pm Bladder Pharmacologic and the Neurogenic Bladder
Adam Philip Klausner, MD
3:15 – 3:30 pm Break
3:30 – 4:30 pm Male Infertility
Puneet Masson, MD
4:30 – 4:45 pm Q&A Session
Tuesday, June 14, 2016
7:00 – 8:00 am Continental Breakfast
Session: Screening, Pediatrics, and Reproductive Biology
8:00 – 9:00 am PSA, Urine Markers and the Science of Cancer Screening
Leonard G. Gomella, MD
9:00 – 10:00 am Intersex
Duong D. Tu, MD
10:00 – 10:15 am Break
10:15 – 11:15 am Reproductive Biology and Sexual Dysfunction in Men and Women
Raymond Anthony Costabile, MD
Session: Pediatric Urology
11:15 am – 12:15 pm Obstructive Uropathy: Valves and UPJO
C.D. Anthony Herndon, MD, FAAP, FACS
12:15 – 1:15 pm Embryology and Congenital Anomalies
Patricio C. Gargollo, MD
Name | Company | Role | Financial |
Trinity J. Bivalacqua, MD | heat biologic
| Scientific Study or Trial
| No
|
photocure | Scientific Study or Trial | No | |
Raymond A. Costabile, MD
| Lilly/Icos
| Consultant or Advisor, Scientific Study or Trial | No |
Vivus
| Scientific Study or Trial | No | |
Paul L. Crispen, M.D.
| Nothing to disclose. | ||
Robert J. Evans, MD
| allergan | Scientific Study or Trial | Yes |
urigen | Investment Interest | Yes | |
allergan | Scientific Study or Trial | Yes | |
TARIS | Scientific Study or Trial | Yes | |
aquinox
| Consultant or Advisor, Scientific Study or Trial
| Yes | |
Patricio C. Gargollo, MD
| Nothing to disclose. | ||
Leonard G. Gomella, MD
| Astellas | Consultant or Advisor | Yes |
Janssen | Consultant or Advisor | Yes | |
Dendreon | Consultant or Advisor, Scientific Study or Trial | Yes | |
Wolters Kluwer | Health Publishing | Yes | |
McGraw Hill | Health Publishing | Yes | |
Merck Manual | Health Publishing | Yes | |
Canadian Journal of Urology | Health Publishing | Yes | |
MDx Health | Consultant or Advisor | Yes | |
Merck Pharmaceuticals | Consultant or Advisor | Yes | |
Bayer | Consultant or Advisor | Yes | |
Mikel L. Gray, Ph.D. | Laborie Medical | Meeting Participant or Lecturer | Yes |
3M Inc. | Consultant or Advisor | Yes | |
C.D. Anthony Herndon, MD, FAAP, FACS
| Nothing to disclose. | ||
Adam Philip Klausner, MD
| Nothing to disclose. | ||
Tracey Krupski, MD | Argos | Scientific Study or Trial | No |
NCI- RAZOR | Scientific Study or Trial | No | |
Richard K. Lee, MD | Nothing to disclose | ||
W. Marston Linehan, MD | Nothing to disclose. | ||
Michael A. Liss, MD | Nothing to disclose. | ||
Puneet Masson, MD | Nothing to disclose. | ||
Afshan Ornan ,M.D. | Nothing to disclose. | ||
Gladell Paner, MD
| Nothing to disclose. | ||
Glenn M. Preminger, MD | Boston Scientific | Consultant or Advisor | Yes |
Olympus | Meeting Participant or Lecturer | Yes | |
Endourological Society | Leadership Position | Yes | |
UpToDate | Health Publishing | Yes | |
Retrophin | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
Jay D. Raman, MD | American Kidney Stone Management | Investment Interest | Yes |
Charles D. Scales Jr., MD | NIH/National Institute on Aging | Scientific Study or Trial | Yes |
American Geriatrics Society | Scientific Study or Trial | Yes | |
Society of Urology Chairpersons and Program Directors | Scientific Study or Trial | Yes | |
Pfizer/National Comprehensive Cancer Network | Scientific Study or Trial | Yes | |
Eric A. Singer, MD | Nothing to disclose. | ||
Necole M Streeper, M.D. | Nothing to disclose. | ||
Duong D. Tu, M.D. | Nothing to disclose. | ||
Michael B. Williams, M.D. | Astellas | Consultant or Advisor | Yes |
Jannsen | Consultant or Advisor | Yes | |
Pacific Health Laboratories | Consultant or Advisor | Yes | |
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation:The American Urological Association designates this live activity for a maximum of 25.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence-Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-Label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by the presenters and planners of educational content in this program are their own and do not necessarily represent the viewpoint of the AUA.
Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Special Assistance: The American Urological Association complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
Available Credit
- 25.50 AMA PRA Category 1 Credit™
- 25.50 Non-Physician Participation